checkAd

     211  0 Kommentare Teva Announces Launch of its Generic Version of Canasa (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States

    Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 1000 mg strength generic version of Casana1 (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the U.S.

    Ulcerative colitis (UC) results in inflammation or swelling of the rectum (the area between the colon and the anus). This inflammation may cause symptoms like bleeding, stomach pain, diarrhea, and urgency (a sudden urge to go to the bathroom). Ulcerative proctitis is common in people who have inflammatory bowel disease (IBD),2 and three times more common than Crohn disease (CD).3

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Teva Pharmaceutical Industries Ltd ADR!
    Long
    13,36€
    Basispreis
    0,83
    Ask
    × 13,48
    Hebel
    Short
    15,09€
    Basispreis
    1,13
    Ask
    × 9,91
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    “Teva’s generic mesalamine suppository is an important treatment option for the 1 million people in the U.S. affected with ulcerative colitis,”4 said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA.

    With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the U.S. Currently, 1 in 11 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

    Mesalamine suppositories have annual sales of more than $74 million in the U.S., according to IQVIA data as of February 2021.

    About Mesalamine Suppositories

    Mesalamine suppositories are a prescription medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis).

    It is not known if mesalamine suppositories are safe and effective in children.

    IMPORTANT SAFETY INFORMATION

    Do not use mesalamine suppositories if you are:

    • allergic to medicines that contain salicylates, including aspirin.

    • allergic to mesalamine or any of the ingredients in mesalamine suppositories.

    Ask your doctor if you are not sure if your medicine is included above.

    Before using mesalamine suppositories, tell your doctor if you:

    • have a history of allergic reaction to the medicine sulfasalazine (Azulfidine).

    • have kidney problems.

    • have ever had inflammation of the sac around your heart (pericarditis).

    • have liver problems.

    • have any other medical conditions.

    • are pregnant or plan to become pregnant. It is not known if mesalamine suppositories can harm your unborn baby.

    • are breastfeeding or plan to breastfeed. Mesalamine can pass into your breast milk. Talk to your doctor about the best way to feed your baby if you use mesalamine suppositories.

    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

    Seite 1 von 4


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Teva Announces Launch of its Generic Version of Canasa (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 1000 mg strength generic version of Casana1 (mesalamine) suppository medicine used to treat adults with …